Xcout IntelLucid Diagnostics Inc.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Subscribe to see Lucid Diagnostics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Lucid Diagnostics Inc. at a glance
Lucid Diagnostics Inc. is a medical devices company headquartered in New York City, United States. It is publicly listed (LUCD) with a market capitalisation of $119.1M. Xcout tracks 29 named people at Lucid Diagnostics Inc., including Lishan Aklog (Chairman & Chief Executive Officer).
Lucid Diagnostics Inc. leadership
- Lishan AklogChairman & Chief Executive Officer
- Shaun O'NeillPresident & Chief Operating Officer
- Dennis McGrathChief Financial Officer
- Dennis M McgrathChief Financial Officer
- Brian J. deGuzmanChief Technology & Compliance Officer
- Suman VermaSenior VP & Chief Scientific Officer
23 more named people on record for Lucid Diagnostics Inc., with roles, board committees and tenure — see the full roster →
Lucid Diagnostics Inc. competitors
A few of Lucid Diagnostics Inc.'s closest competitors — see the full list of competitors and alternatives →
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
The Reflux Company provides patient-centered diagnostic and therapeutic solutions for individuals suffering from gastroesophageal reflux. The company offers a portfolio of FDA-cleared products, including the Restech Dx-pH upper airway test, the Stretta incision-free procedure for chronic GERD, the Reflux Band nighttime sleep device, and the at-home PepsinCheck saliva test.
EnteroTrack, LLC provides the Esophageal String Test (EST) using its EnteroTracker device, offering a minimally invasive, non-endoscopic tool for clinicians to collect upper gastrointestinal samples and monitor Eosinophilic Esophagitis (EoE) activity in patients. The office-based procedure helps assess mucosal inflammation and biomarkers over time, potentially reducing the need for repeated endoscopies.
Origin Sciences is a medical technology company based in the UK that develops innovative devices and tests to aid in the detection and diagnosis of gastrointestinal diseases.
LuminX Global, Inc. develops medical devices and diagnostic software for dentistry, specifically focusing on subgingival diagnostics for gum disease detection. Its flagship product, the LuminX Probe, uses sensor-based measurements and imaging technology to automate periodontal charting for dental professionals, hygienists, and periodontists.
Laborie Medical Technologies Corp. is a medical technology company headquartered in Portsmouth, New Hampshire. The company specializes in medical devices and diagnostics for specialties such as urology and gastroenterology.
Get Lucid Diagnostics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Lucid Diagnostics Inc. in Xcout Intel
- 29 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access